Sanofi is currently seen as an investment opportunity with significant upside potential, trading at a notable discount compared to its calculated fair value. The pharmaceutical giant demonstrates strong growth driven by its leading drug, Dupixent, and a robust pipeline of future medications. This foundation supports a projected annual earnings per share (EPS) growth of over 9% through to 2028, significantly outpacing its historical valuation metrics.

Furthermore, Sanofi offers an attractive dividend yield, supported by a history of consistent annual increases and a sustainable payout ratio. This combination of growth and income makes it an appealing prospect for investors. However, potential risks need to be acknowledged, such including the upcoming patent expiration of Dupixent in the early 2030s and the evolving landscape of U.S. drug pricing legislation, which could impact future profitability.

As the global population ages, the demand for healthcare solutions will continue to rise, positioning pharmaceutical companies like Sanofi at the forefront of a growing market. With a strong financial standing, innovative research and development, and a commitment to shareholder returns, Sanofi is well-positioned to capitalize on these demographic shifts and deliver long-term value to investors. Investing in companies that address the needs of an older demographic can lead to sustained growth and positive societal impact.